PR Newswire
ROCKVILLE, Md., Oct. 2, 2018
ROCKVILLE, Md., Oct. 2, 2018 /PRNewswire/
-- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the
curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will
present at the Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9,
2018 at 4:15 p.m. ET at the Westin Grand Central, New
York.
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available on the
same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding
one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
CONTACT:
Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com
Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-chardan-2nd-annual-genetic-medicines-conference-300723170.html
SOURCE REGENXBIO Inc.